Image For Activity Cover
Targeting Inflammation in Atherosclerotic Disease - The New Frontier
Overview

Jennifer A. Rymer, MD, MBA, MHS

Moderator and Speaker

Binita Shah, MD, MS, FSCAI

Moderator and Speaker

Wayne B. Batchelor, MD, FSCAI

Speaker

Joshua Beckman, MD, MSc

Speaker


Welcome and CME Information, Jennifer A. Rymer, MD, MBA, MHS

The History and Mechanism of Anti-Inflammatory Agents in the Treatment of ASCVD, Joshua Beckman, MD, MSc

Unlocking the Story of Colchicine and Its Role in the Treatment of Coronary Artery Disease, Binita Shah, MD, MS, FSCAI
Residual Inflammatory Risk in the PostPCI/AMI Patient: How Do We Define and Reduce These Risks? Wayne B. Batchelor, MD, FSCAI

Novel Therapies for Targeting Inflammation in ASCVD, Jennifer A. Rymer, MD, MBA, MHS

Acknowledgment of Commercial Support ​

This activity is supported by an unrestricted educational grant from Novo Nordisk.

Learning Objectives

At the end of this activity, participants should be able to: 

1. Examine the mechanism by which anti-inflammatory therapies may improve cardiovascular outcomes in patients with ASCVD.  

2. Discuss the recently published trial data on therapies, including colchicine.  

3. Describe novel therapies currently being tested, as well as other potential ASCVD disease states that may benefit from anti-inflammatory therapies.

Disclosures

PLANNER

Jennifer Rymer: No relevant financial relationships with ineligible companies.


FACULTY

Wayne Batchelor, Jennifer Rymer, Binita Shah: No relevant financial relationships with ineligible companies.

Joshua Beckman: Tourmaline Bio - Consulting; Novartis – Consulting.

REVIEWER

Binita Shah: No relevant financial relationships with ineligible companies.


SCAI STAFF

Laura Porter: No financial relationships with ineligible companies 

Continuing Education Information

Accreditation Statement
The Society for Cardiovascular Angiography and Interventions (SCAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.​

​Credit Designation
SCAI designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.​

​ABIM MOC
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.​

Successful Completion
Watch the content and complete the evaluation to obtain credit.

Activity Timeline
Record date: May 2, 2025
Publish date: June 30, 2025
Retire date: April 17, 2026

SCAI's Independent Content

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities.

Planning Process 
SCAI activities are developed by the SCAI planners prior to and independent of commercial support. Members of the Program Committee reviewed and approved this activity. If planners had relevant financial relationships, the agenda was peer reviewed by a member with no relevant financial relationships.

Mitigation of Relevant Financial Relationships
All participating planners, reviewers, faculty, and staff are required to disclose to SCAI all financial relationships with ineligible companies. SCAI identifies relevant financial relationships and mitigates them before the activity begins. 

Content Validation Statement
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations.

All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. SCAI does not promote recommendations, treatment, or manners of practicing medicine that are not within the definition of accredited continuing education or known to have risks or dangers that outweigh the benefits or known to be ineffective in the treatment of patients.

All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis. 

SCAI actively promotes improvements in health care and NOT proprietary interests of an ineligible company. SCAI's educational content is free of marketing or sales of products or services.

Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration (FDA), at first mention and where appropriate in the content.

Copyright
© 2025 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.
Summary
Availability:
On-Demand
Access expires on Apr 17, 2026
Cost:
FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 Participation Credit
Powered By